• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

引入一种整合的初级保健粪便免疫化学检测转诊途径,用于疑似结直肠癌症状的患者。

Introduction of an integrated primary care faecal immunochemical test referral pathway for patients with suspected colorectal cancer symptoms.

机构信息

Croydon University Hospital, London, UK.

Imperial College London, London, UK.

出版信息

Colorectal Dis. 2022 Dec;24(12):1526-1534. doi: 10.1111/codi.16294. Epub 2022 Aug 23.

DOI:10.1111/codi.16294
PMID:35934985
Abstract

AIM

To determine the efficacy of a new 2-week wait pathway that uses the faecal immunochemical test (FIT) in primary care to triage patients with high and low risk symptoms suspicious of colorectal cancer (CRC). This service improvement pilot follows 2017 National Institute for Health and Care Excellence guidance, that recommended using FIT to guide referral of patients with low risk, but not high risk symptoms, which continue to be referrred on the 2-week pathway.

METHOD

Patients with high- and low-risk CRC symptoms were tested with FIT and those with faecal haemoglobin (f-Hb) ≥9.5 μg haemoglobin/g faeces (hereafter μg/g) were referred to secondary care. Results were tracked and primary care prompted to refer if timely referral was not made.

RESULTS

Between December 2019 and October 2020, 5672 patients presented to primary care with high and/or low risk symptoms warranting investigations. Of these, 622 (11%) patients were referred without a FIT, of whom 36 (5.8%) had CRC. The remaining 5050 patients had a FIT, of which 4187 (83%) were processed to produce a quantitative result. Of these, 1085 patients (25.9%) had an f-Hb ≥9.5 μg/g and of those, 982 patients (90.5%) were referred and 56 (5.7%) had CRC. A total of 3102 patients (74.1%) had an f-Hb <9.5 μg/g, of which 456 (14.7%) were referred and three (0.7%) had CRC. A total of 97 cancers were diagnosed with a cancer prevalence of 1.7%.

CONCLUSION

A 2-week wait pathway incorporating FIT as a triage tool can be implemented successfully in primary care to identify symptomatic patients at highest risk of CRC.

摘要

目的

确定一种新的 2 周等待途径在初级保健中的疗效,该途径使用粪便免疫化学测试(FIT)对疑似结直肠癌(CRC)的高风险和低风险症状患者进行分诊。这项服务改进试点遵循 2017 年国家卫生与保健卓越研究所的指导建议,该建议建议使用 FIT 来指导低风险但无高风险症状患者的转诊,这些患者继续在 2 周途径中转诊。

方法

对具有高风险和低风险 CRC 症状的患者进行 FIT 检测,粪便血红蛋白(f-Hb)≥9.5μg 血红蛋白/g 粪便(以下简称μg/g)的患者被转诊至二级保健。结果进行了跟踪,如果没有及时转诊,初级保健会收到提示。

结果

2019 年 12 月至 2020 年 10 月期间,5672 名具有高风险和/或低风险症状的患者到初级保健就诊,需要进行检查。其中,622 名(11%)患者未经 FIT 检测就被转诊,其中 36 名(5.8%)患有 CRC。其余 5050 名患者进行了 FIT 检测,其中 4187 名(83%)产生了定量结果。其中,1085 名患者(25.9%)的 f-Hb≥9.5μg/g,其中 982 名患者(90.5%)被转诊,56 名(5.7%)患有 CRC。共有 3102 名患者(74.1%)的 f-Hb<9.5μg/g,其中 456 名(14.7%)被转诊,3 名(0.7%)患有 CRC。共有 97 例癌症被诊断,癌症患病率为 1.7%。

结论

在初级保健中实施包含 FIT 作为分诊工具的 2 周等待途径,可以成功识别最有可能患有 CRC 的有症状患者。

相似文献

1
Introduction of an integrated primary care faecal immunochemical test referral pathway for patients with suspected colorectal cancer symptoms.引入一种整合的初级保健粪便免疫化学检测转诊途径,用于疑似结直肠癌症状的患者。
Colorectal Dis. 2022 Dec;24(12):1526-1534. doi: 10.1111/codi.16294. Epub 2022 Aug 23.
2
Service evaluation of faecal immunochemical testing and anaemia for risk stratification in the 2-week-wait pathway for colorectal cancer.粪便免疫化学检测和贫血用于结直肠癌 2 周等待路径风险分层的服务评估。
BJS Open. 2019 Jan 28;3(3):395-402. doi: 10.1002/bjs5.50131. eCollection 2019 Jun.
3
Prevalence of repeat faecal immunochemical testing in symptomatic patients attending primary care.在初级保健就诊的有症状患者中重复粪便免疫化学检测的流行率。
Colorectal Dis. 2022 Dec;24(12):1498-1504. doi: 10.1111/codi.16240. Epub 2022 Jul 18.
4
Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: A community-based cohort study.定量粪便免疫化学检测阳性阈值在初级保健中用于结直肠癌检测的最佳诊断准确性:一项基于社区的队列研究。
United European Gastroenterol J. 2021 Mar;9(2):256-267. doi: 10.1177/2050640620949714. Epub 2021 Mar 1.
5
High-risk symptoms and quantitative faecal immunochemical test accuracy: Systematic review and meta-analysis.高危症状与定量粪便免疫化学检测的准确性:系统评价和荟萃分析。
World J Gastroenterol. 2019 May 21;25(19):2383-2401. doi: 10.3748/wjg.v25.i19.2383.
6
Yield of colorectal cancer at colonoscopy according to faecal haemoglobin concentration in symptomatic patients referred from primary care.基于初级保健转介的有症状患者粪便血红蛋白浓度的结肠镜检查对结直肠癌的检出率。
Colorectal Dis. 2021 Jul;23(7):1615-1621. doi: 10.1111/codi.15405. Epub 2020 Nov 1.
7
Impact of faecal haemoglobin based triage of bowel symptoms presenting to primary care on colorectal cancer diagnosis.基于粪便血红蛋白的初级保健中肠道症状分诊对结直肠癌诊断的影响。
Colorectal Dis. 2023 Apr;25(4):787-793. doi: 10.1111/codi.16451. Epub 2022 Dec 28.
8
A comparison of the faecal haemoglobin concentrations and diagnostic accuracy in patients suspected with colorectal cancer and serious bowel disease as reported on four different faecal immunochemical test systems.比较四种不同粪便免疫化学检测系统报告的疑似结直肠癌和严重肠道疾病患者的粪便血红蛋白浓度和诊断准确性。
Clin Chem Lab Med. 2022 Jun 1;60(8):1278-1286. doi: 10.1515/cclm-2021-1248. Print 2022 Jul 26.
9
Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.粪便免疫化学检测用于在初级保健中对有下腹部症状的患者进行分流,以确定是否需要转诊疑似结直肠癌患者:一项系统评价和成本效益分析。
Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330.
10
Using the faecal immunochemical test in patients with rectal bleeding: evidence from the NICE FIT study.在有直肠出血症状的患者中使用粪便免疫化学检测:来自 NICE FIT 研究的证据。
Colorectal Dis. 2021 Jul;23(7):1630-1638. doi: 10.1111/codi.15593. Epub 2021 Mar 15.

引用本文的文献

1
Faecal immunochemical tests for patients with symptoms suggestive of colorectal cancer: An updated systematic review and multiple-threshold meta-analysis of diagnostic test accuracy studies.针对有结直肠癌疑似症状患者的粪便免疫化学检测:诊断试验准确性研究的最新系统评价和多阈值Meta分析
Colorectal Dis. 2024 Dec 17;27(1). doi: 10.1111/codi.17255.